POLY(ISOBUTYLENE-ALT-MALEIC ANHYDRIDE)
POLY(ISOBUTYLENE-ALT-MALEIC ANHYDRIDE) structure
|
Common Name | POLY(ISOBUTYLENE-ALT-MALEIC ANHYDRIDE) | ||
|---|---|---|---|---|
| CAS Number | 26426-80-2 | Molecular Weight | 154.16300 | |
| Density | 1.3 g/mL at 25ºC(lit.) | Boiling Point | 202ºC at 760 mmHg | |
| Molecular Formula | C8H10O3 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 103.3ºC | |
|
Towards biocompatible vaccine delivery systems: interactions of colloidal PECs based on polysaccharides with HIV-1 p24 antigen.
Biomacromolecules 9(2) , 583-91, (2008) This work reports on the interactions of a model protein (p24, the capside protein of HIV-1 virus) with colloids obtained from polyelectrolyte complexes (PECs) involving two polysaccharides: chitosan and dextran sulfate (DS). The PECs were elaborated by a one... |
|
|
Delivering the goods.
Dalton Trans. (11) , C23, (2007)
|
|
|
Shell cross-linked hyaluronic acid/polylysine layer-by-layer polyelectrolyte microcapsules prepared by removal of reducible hyaluronic acid microgel cores.
Biomacromolecules 8(12) , 3705-11, (2007) Shell cross-linked hollow polyelectrolyte microcapsules composed of hyaluronic acid (HA) and poly- l-lysine (PLL) were prepared by layer-by-layer (LBL) adsorption and subsequent core removal by a reductive agent. Disulfide cross-linked HA microgels were used ... |
|
|
Electric field induced phase separation on electrospinning polyelectrolyte based core-shell nanofibers.
Carbohydr. Polym. 90(4) , 1582-6, (2012) In the present study, we report a facile method to fabricate polyelectrolyte based core-shell nanofibers with the assistance of the high gradient electric potential between the tip of capillary and the collector. The core-shell structure and the composition o... |
|
|
Structural transformation of apocytochrome c induced by alternating copolymers of maleic acid and alkene.
Biomacromolecules 6(5) , 2748-55, (2005) Apocytochrome c interacts with two copolymers: poly(isobutylene-alt-maleic acid) (PIMA) and poly(1-tetradecene-alt-maleic acid) (PTMA). The interaction leads to apocytochrome c, a conformational change from random coil to alpha-helical structure. The alpha-he... |
|
|
Controlled release of repifermin from polyelectrolyte complexes stimulates endothelial cell proliferation.
J. Pharm. Sci. 98(1) , 268-80, (2009) The therapeutic value of many growth factors is often hindered by the narrow therapeutic index and sustained concentrations required for efficacy. Controlled release approaches provide a valuable tool to achieve these goals; however, growth factor stability m... |
|
|
Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy.
Nanotechnology 22(26) , 265101, (2011) The use of cisplatin, a first line chemotherapy for most cancers, is dose-limited due to nephrotoxicity. While this toxicity can be addressed through nanotechnology, previous attempts at engineering cisplatin nanoparticles have been limited by the impact on t... |
|
|
Polyelectrolyte-coated alginate microspheres as drug delivery carriers for dexamethasone release.
Drug Deliv. 16(6) , 331-40, (2009) Alginate microspheres loaded with dexamethasone were prepared by the droplet generator technique. Important parameters affecting drug release, including initial drug content, the type of polyelectrolyte coating, and a combination of different ratios of coated... |
|
|
Polyelectrolyte-drug complexes of lambda carrageenan and basic drugs: relevance of particle size and moisture content on compaction and drug release behavior.
Drug Dev. Ind. Pharm. 34(11) , 1188-95, (2008) The interaction between polyelectrolytes (PE) and oppositely charged drugs (D) results in complexes (PE-D) that can be exploited in controlled release drug delivery systems. The aim of this work is to better understand the relevance of some preparative parame... |
|
|
Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII.
Blood 63(1) , 31-41, (1984) Circulating antibodies to factor VIII (anti-VIII, "inhibitors") occurring in patients with hemophilia neutralize porcine factor VIII less readily than human factor VIII in vitro. Over an 18-mo period, 8 patients with anti-VIII were treated with 45 courses (29... |